Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law FirmPR NewswireNEW YORK, Oct. 12, 2026NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC,
IMVT - Immunovant, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$40.00
DETAILS
HIGH:
$40.00
LOW:
$40.00
MEDIAN:
$40.00
CONSENSUS:
$40.00
UPSIDE:
49.64%
Stock News
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm
NEW YORK, Oct. 12, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law
[url="]Schall, Brown and Schwartz[/url] LLP (âSBSâ), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of inv
IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $IMVT--IMVT Investors with $100,000 in Losses Have Opportunity to Join Immunovant, Inc. Fraud Investigation with SBS Law.
Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT)
Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT)PR NewswireNEW YORK, Sept. 25, 2026Immunovant stock
Immunovant Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Immunovant (IMVT)
Immunovant stock fell roughly 6% to a more-than-three-month low on September 23, 2026 after the IMVT-1402 cutaneous lupus study missed its primary endpoint. SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of IMVT investors who lost money.
IMVT Ends Cutaneous Lupus Erythematosus Program, Stock Down
Immunovant's IMVT-1402 misses its primary CLE goal, prompting the company to halt the program despite positive trends and a favorable safety profile.
Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
Immunovant's proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) percent change from baseline at Week 12 Positive trends were observed on multiple endpoints, with deeper IgG reductions resulting in improved clinical outcomes, but the study did not meet Immunovant's internal bar to continue development of IMVT-1402 in CLE IMVT-1402 demonstrated a favorable safety and tolerability profile, consistent with prior studies All other clinical development timelines remain on track BASEL, Switzerland and LONDON and NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced topline results from Period 1 of Immunovant's proof-of-concept trial evaluating IMVT-1402 (imeroprubart) for the treatment of cutaneous lupus erythematosus (CLE).
Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
Immunovant's proof-of-concept study of IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus (CLE) did not achieve statistical significance on the primary endpoint of Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) percent change from baseline at Week 12 Positive trends were observed on multiple endpoints, with deeper IgG reductions resulting in improved clinical outcomes, but the study did not meet Immunovant's internal bar to continue development of IMVT-1402 in CLE IMVT-1402 demonstrated a favorable safety and tolerability profile, consistent with prior studies All other clinical development timelines remain on track DURHAM, N.C., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced topline results from Period 1 of its proof-of-concept trial evaluating IMVT-1402 (imeroprubart) for the treatment of cutaneous lupus erythematosus (CLE).
Algert Global LLC Raises Position in Immunovant, Inc. $IMVT
Algert Global LLC increased its stake in Immunovant, Inc. (NASDAQ: IMVT) by 51.1% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 159,840 shares of the company's stock after buying an additional 54,070 shares during the quarter. Algert Global LLC owned about
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm
NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
Immunovant (NASDAQ:IMVT) Sets New 12-Month High – Still a Buy?
Shares of Immunovant, Inc. (NASDAQ: IMVT - Get Free Report) reached a new 52-week high during mid-day trading on Tuesday. The company traded as high as $43.89 and last traded at $43.71, with a volume of 1216514 shares. The stock had previously closed at $41.82. Wall Street Analysts Forecast Growth A number of analysts recently
Immunovant, Inc. (IMVT) Q1 2027 Earnings Call Transcript
Immunovant, Inc. (IMVT) Q1 2027 Earnings Call Transcript
Immunovant Q1 Earnings Call Highlights
Roivant said its first quarter was relatively quiet operationally but positioned the company for a more active second half of 2026, with a potential launch of brepocitinib in dermatomyositis, multiple clinical readouts and further updates from Immunovant NASDAQ: IMVT.
Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress
IMVT posts a wider quarterly loss as R&D spending rises, but its cash runway supports IMVT-1402 through a planned Graves' disease commercial launch.
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026
All IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves' disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), difficult-to-treat rheumatoid arthritis (D2T RA), Sjögren's disease (SjD) and cutaneous lupus erythematosus (CLE) Current cash balance provides runway to the potential launch of IMVT-1402 in GD Roivant will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 6, 2026 DURHAM, N.C.
Immunovant: Risk-Reward Set-Up Compelling, Initiating With A Speculative Buy
I initiate coverage of Immunovant with a BUY rating and a $50 price target, driven by optimism around IMVT-1402's differentiated profile. IMVT-1402 demonstrates strong IgG reduction with minimal albumin and LDL impact, potentially best-in-class, with Graves' disease as the principal valuation driver. My valuation assumes ~$4B probability-adjusted peak sales and a conservative 2.5x sales multiple, supporting a ~$10.9B equity value, or $50 per share.
Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm
NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?
Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock?
Immunovant Stock Gains 12.4% in a Month: What's Driving It?
IMVT shares climb as IMVT-1402 posts encouraging data, advances across autoimmune diseases and benefits from a cash runway extending through launch.
Price Targets
Immunovant (IMVT) PT Raised to $40 at H.C. Wainwright
$40.00
(was $35.56)
Douglas Tsao
·
H.C. Wainwright
Immunovant upgraded to Outperform at Wolfe on improving Graves' perception
$50.00
(was $24.97)
Wolfe Research
Immunovant price target lowered to $41 from $44 at Guggenheim
$41.00
(was $26.27)
Yatin Suneja
·
Guggenheim
Immunovant initiated with a Hold at Truist
$16.00
(was $17.35)
Truist Financial
H.C. Wainwright Reiterates Buy Rating on Immunovant (IMVT)
$51.00
(was $30.20)
Douglas Tsao
·
H.C. Wainwright
Immunovant price target lowered to $46 from $50 at Oppenheimer
$46.00
(was $25.39)
Leland Gershell
·
Oppenheimer
Immunovant (IMVT) PT Lowered to $48 at Guggenheim
$48.00
(was $26.41)
Yatin Suneja
·
Guggenheim
Piper Sandler Reiterates Overweight Rating on Immunovant (IMVT)
$57.00
(was $27.83)
Yasmeen Rahimi
·
Piper Sandler
Goldman Sachs Starts Immunovant (IMVT) at Buy
$50.00
(was $31.82)
Corinne Johnson
·
Goldman Sachs
Immunovant downgraded to Neutral from Buy at UBS
$5.00
(was $4.88)
Colin Bristow
·
UBS